Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.
Stojković Burić, Sonja
Article (Published version)
© Bentham Science Publishers
MetadataShow full item record
BACKGROUND Dual-targeting in cancer treatment by a single drug is an unconventional approach in relation to drug combinations. The rationale for the development of dualtargeting agents is to overcome incomplete efficacy and drug resistance frequently present when applying individual targeting agents. Consequently, -a more favorable outcome of cancer treatment is expected with dual-targeting strategies. METHODS We reviewed the literature, concentrating on the association between clinically relevant and/or novel dual inhibitors with the potential to modulate multidrug resistant phenotype of cancer cells, particularly the activity of P-glycoprotein. A balanced analysis of content was performed to emphasize the most important findings and optimize the structure of this review. RESULTS Two-hundred and forty-five papers were included in the review. The introductory part was interpreted by 9 papers. Tyrosine kinase inhibitors' role in the inhibition of Pglycoprotein and chemosensitization was illustrated by 87 papers. The contribution of naturalbased compounds in overcoming multidrug resistance was reviewed using 92 papers, while specific dual inhibitors acting against microtubule assembling and/or topoisomerases were described with 55 papers. Eleven papers gave an insight into a novel and less explored approach with hybrid drugs. Their influence on P-glycoprotein and multidrug resistance was also evaluated. CONCLUSION These findings bring into focus rational anticancer strategies with dual-targeting agents. Most evaluated synthetic and natural drugs showed a great potential in chemosensitization. Further steps in this direction are needed for the optimization of anticancer treatment.
Keywords:P-glycoprotein; Hybrid compounds; Microtubule interacting agents; Multidrug resistance; Naturalbased; Drugs; Targeted anticancer therapy; Topoisomerase inhibitors; Tyrosine kinase inhibitors.
Source:Current Medicinal Chemistry, 2019, 26, 33, 6074-6106
- Identification of predictive molecular markers for cancer progression, response to therapy and disease outcome (RS-41031)